NewAmsterdam Pharma Company N.V. NAMS PHARMA
Company Overview
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.01.
Recent Developments
- Dec 2025 Revenue of $22.50M (-50.6% YoY); net profit $-203.82M.
- Trailing 12 Months Year-on-year growth — revenue -80.7%.
- 5-Year Trend Long-term compounding — revenue CAGR -39.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -39.71% |
| 1 Year: | -80.70% |
Stock Price Performance
| 1 Year: | -0.50% |
| 6 Months: | -16.70% |
| 3 Months: | -17.19% |
| 1 Month: | -8.33% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)38.73 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -39.7% CAGR over 5 years.
- Trading 38.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NAMS NewAmsterdam Pharma Company N.V. PHARMA | 25.63 | -11.87 | $3.06B | 0.00% | -33.02% | -36.81% | -39.71% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.63M | 1.72M | 2.94M | 1.40M | 2.28M | 29.11M | 2.98M | 19.14M | 348.00K | 32.00K | 3.04M | 3.70M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | 71.90M | 54.78M | 55.49M | 66.01M | 61.46M | - |
| Operating Income | -39.85M | -42.48M | -49.56M | -55.48M | -52.58M | -25.00M | -68.92M | -35.63M | -55.14M | -65.98M | -58.42M | -64.86M |
| EBITDA | - | - | - | - | - | - | -68.87M | -35.59M | -55.08M | -65.92M | -58.36M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | -39.53M | -17.36M | -72.00M | -74.92M | -48.44M | - |
| Tax Provision | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - |
| Net Income | -42.02M | -38.29M | -47.13M | -93.77M | -39.01M | -16.65M | -39.53M | -17.36M | -72.00M | -74.92M | -48.44M | -64.14M |
| Diluted EPS | -0.51 | -0.47 | -0.57 | -1.06 | -0.41 | -0.18 | -0.34 | -0.15 | -0.61 | - | -0.40 | -0.52 |
| R&D Expense | 40.42M | 34.34M | 43.37M | 42.43M | 38.38M | 35.70M | 44.75M | 27.52M | 30.97M | - | 38.01M | 41.67M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 102.69M | 14.09M | 45.56M | 22.50M |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 106.25M | 197.06M | 221.85M | 248.19M |
| Operating Income | - | -3.56M | -182.97M | -176.29M | -225.68M |
| EBITDA | - | -22.34M | -182.92M | -176.18M | -225.46M |
| Interest Expense | 411.00K | 287.00K | 0 | 0 | - |
| Pretax Income | - | -22.63M | -176.91M | -241.60M | -203.82M |
| Tax Provision | - | 0 | 27.00K | -1.00K | 0 |
| Net Income | - | -22.63M | -176.94M | -241.60M | -203.82M |
| Diluted EPS | - | -1.19 | -2.15 | -2.56 | -1.78 |
| R&D Expense | 28.97M | 86.74M | 159.42M | 151.41M | 141.83M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | - | - | 478.50M | 347.10M | 864.62M | 769.28M |
| Current Assets | - | - | 477.98M | 346.79M | 863.41M | 675.70M |
| Cash & Equivalents | - | - | 467.73M | 340.45M | 771.74M | 490.00M |
| Inventory | - | - | - | - | - | - |
| Receivables | - | - | 2.07M | 1.88M | 21.30M | 23.15M |
| Total Liabilities | - | - | 48.43M | 58.70M | 107.12M | 85.85M |
| Current Liabilities | - | - | 36.06M | 49.90M | 106.92M | 85.79M |
| Long Term Debt | - | - | - | - | - | - |
| Total Debt | - | - | 126.00K | 60.00K | 448.00K | 202.00K |
| Total Equity | -73.03M | - | 430.07M | 288.39M | 757.50M | 683.43M |
| Shares Outstanding | - | - | 81.56M | 82.47M | 108.06M | 114.40M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 10.66M | -141.22M | -158.56M | -147.78M |
| Investing Cash Flow | - | -221.00K | -24.00K | -62.85M | -174.92M |
| Financing Cash Flow | - | 391.90M | 8.91M | 659.51M | 29.52M |
| Capital Expenditure | - | -221.00K | -24.00K | -672.00K | -246.00K |
| Free Cash Flow | - | 10.44M | -141.24M | -159.24M | -148.03M |
| Net Change in Cash | - | 402.35M | -132.33M | 438.10M | -293.18M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | -3.5% | -1,298.6% | -386.9% | -1,002.9% |
| Net Margin % | - | -22.0% | -1,255.8% | -530.3% | -905.7% |
| ROE % | - | -5.3% | -61.4% | -31.9% | -29.8% |
| ROCE % | - | -0.8% | -61.6% | -23.3% | -33.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Frazier Life Sciences Management, L.P. | 15.13% | 18.09M | $406.82M |
| 2 | Capital World Investors | 10.23% | 12.23M | $275.07M |
| 3 | FMR, LLC | 8.65% | 10.34M | $232.54M |
| 4 | RA Capital Management, L.P. | 7.99% | 9.55M | $214.78M |
| 5 | FCPM III Services B.V. | 7.10% | 8.49M | $190.95M |
| 6 | Deerfield Management Company, L.P | 3.57% | 4.26M | $95.92M |
| 7 | Viking Global Investors, L.P. | 3.52% | 4.20M | $94.54M |
| 8 | Bain Capital Life Sciences Investors, LLC | 3.18% | 3.81M | $85.61M |
| 9 | Maverick Capital Ltd. | 2.73% | 3.27M | $73.49M |
| 10 | Duquesne Family Office Llc | 2.57% | 3.07M | $69.05M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NAMS
New hires receive options to buy NewAmsterdam shares at $24.92. Some awards vest over four years. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxNY3JodllnQm5LdlRkVGotLWFKR0xHQTlLWjNNNnlURlJJX0Z4azRSdG5abVNLOHItTnBjTDFTVDNkU1g0UDZLdkQ1a3RpakxYcEJaNzhRQXV4UnR0ODV1LVdYRDNUdXBFZFh5TnJmVl9oUHZMaTU4cnRoVkloRXJnRkpiTjZUcXRxNVd3Ui…
NewAmsterdam Pharma (NAMS) Heads To ESC 2026 With Phase 3 Data, Is It Still 76% Below Fair Value? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxOWkZkTnlrM2dmeGUyQnpobXZqUGUtNTN6U1FrRzZCb3l0dkdIbV94bTBpbGNoX19PQVpNdmMweUdfRGdDN1NfZ19tdTNGT1VrVjYydlBWWnhPR1pLVW5DdXN5UVdKUzA3b0NzODZmTXJ2dmRIUEdYeWJnYlphT3pMUi1LZEpNSlFNUldzZX…
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue Estimates - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxQLU5iWFpPWm1mVkdKdjBKWnppU3V4VnVISGRXZTF1X0JseUUwTklGOTd2UUx4WWlLeVcxTThSemZ4b0ZhZVA3dkZZRFEwUm9mOWc4S0syWnhvZ2ZSaXNDazhmMVRZVmhoazZncGdVMUZuZDk2XzFTVXBNTmdoSWdyYTlsMHFseXdtYzFqWF…
Precision Trading with Newamsterdam Pharma Company N.v. (NAMS) Risk Zones - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxOV29yeGgtRnhzMEJmdDNQM2ZmMTl0RUFyX3RyM2hPMTBQb2pGZzVQT3lYdkhJOXViOW9HVVlnbE1vYWpyV3JFVk0wNWt2WUxfVUMyOTRuc1BaaVp2bU9JSVV4V1ZMX19XTzdrQlBOcGpmaW5CSVdJZ3FvTlNQZWdnY0JVVWloNkNnWlZnan…
NewAmsterdam Pharma (NAMS) awards 14,000 options and 3,200 RSUs to controller - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxPZ0xsVnNETWdadEg0TGZPY2h3NDU0NEZMWk5ReWhheUpFRC1JcXhoX0haNy03anNvcjR4VlRhU2RiNWROR3JlOGozMVBGSjJ1XzZ5QUVWLTFvUHFjQ3FvMFVMTUs5Zml0YUxUSTF2VTQ5bHFwWEMyM3pwMTlUNWpZVjlVTnJIcnYzTHRmNm…
NewAmsterdam Pharma: Obicetrapib Is More Than Another LDL-Lowering Pill - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxQaG5kMEIyM3BTR3I3dWJ5RGw4ZV9oR0RjNEdGY0NNYVI5ZHVfY3JZMk9yWVdNankzTzFEOEJfUVQtWHpvRDRNX3NqTkpwcG93MVBYbzBLTmRCRGNKM29lT2wtWHZjeEhGZGJxWGg1YkFhdzU1Smo2Q0UzTFlXZkxPNlYtRThJajU4ZjJHMD…
NAMS — Frequently Asked Questions
What is the current share price of NewAmsterdam Pharma Company N.V. (NAMS)?
As of 2026-09-19 21:16 PDT, NewAmsterdam Pharma Company N.V. (NAMS) trades at $25.63 on NasdaqGM. Its 52-week range is $23.95 to $41.45.
What is the market capitalisation of NAMS?
NewAmsterdam Pharma Company N.V. (NAMS) has a market capitalisation of $3.06B on NasdaqGM.
What is the P/E ratio of NAMS?
NAMS trades at a trailing price-to-earnings (P/E) ratio of -11.87. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 4.19.
What is the return on equity (ROE) of NAMS?
NAMS has a return on equity (ROE) of -36.81%. Its return on capital employed (ROCE) is -33.02%.
Is NAMS a good stock to buy?
This page provides a data-driven analysis of NewAmsterdam Pharma Company N.V. (NAMS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.